<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Potential interactions between COVID-19 regimen and commonly used HF and transplant medications</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Suggested COVID-19 medication</th>
    <th>Potential HF and transplant patient medication</th>
    <th>Interaction</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="4">Hydroxychloroquine</td>
    <td>Beta blockers</td>
    <td>Hydroxychloroquine inhibits CYP2D6 increasing beta blocker concentration ➔ monitor for bradycardia and AV block</td>
   </tr>
   <tr>
    <td>Antiarrhythmic medications (amiodarone, dofetilide)</td>
    <td>Higher risk of QTc prolongation and TdP</td>
   </tr>
   <tr>
    <td>Cyclosporine</td>
    <td>Hydroxychloroquine may increase serum concentration of cyclosporine through unknown mechanisms</td>
   </tr>
   <tr>
    <td>Digoxin</td>
    <td>Hydroxychloroquine may inhibit p-glycoprotein-mediated digoxin transport ➔ may increase digoxin concentration</td>
   </tr>
   <tr>
    <td rowspan="6">Lopinavir/ritonavir (Lpv/R)</td>
    <td>Antiarrhythmic medications (amiodarone, dofetilide)</td>
    <td>Lpv/R inhibits CYP3A4 ➔ increase in antiarrhythmic concentration, side effects, and QTc prolongation</td>
   </tr>
   <tr>
    <td>Eplerenone</td>
    <td>Lpv/R inhibits CYP3A4 ➔ increase in concentration of eplerenone</td>
   </tr>
   <tr>
    <td>Ivabradine</td>
    <td>Lpv/R inhibits CYP3A4 ➔ increase in concentration of ivabradine</td>
   </tr>
   <tr>
    <td>Cyclosporine</td>
    <td>Lpv/R inhibits CYP3A4 ➔ increase in concentration of tacrolimus</td>
   </tr>
   <tr>
    <td>Tacrolimus</td>
    <td>Lpv/R inhibits CYP3A4 ➔ increase in concentration of tacrolimus</td>
   </tr>
   <tr>
    <td>Warfarin (VKA)</td>
    <td>Lpv/R may decrease VKA concentration through induction of metabolism (CYP2C9) and other uncertain mechanisms</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
